Clinical Trial Update: Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This document reports on a phase 1/2 clinical trial evaluating the safety and efficacy of Atiprimod in patients with refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Atiprimod

Snippet

Sponsor: Callisto Pharmaceuticals | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED